RxDoctor Payments Data

Tracie Thornton

Nurse Practitioner · Gadsden, ALNPI 1467962472

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 490 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,696in general payments, 2019–2025

Across 490 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Johnson & Johnson$756
  • Incyte Corporation$649
  • E.r. Squibb & Sons, L.L.C.$633
  • Novartis$612
  • Pfizer$591
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$9,25595%
  • Education$4415%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)54$1,061
Johnson & Johnson39$756
Incyte Corporation26$649
E.r. Squibb & Sons, L.L.C.44$633
Novartis38$612
Pfizer43$591
Merck19$458
Seagen Inc.19$441
Bristol Myers Squibb5$290
Astellas Pharma US Inc10$281
Amgen15$229
Array Biopharma Inc13$221
Pharmaessentia USA Corporation8$215
Lilly USA, LLC11$210
Takeda Pharmaceuticals U.S.A., Inc.7$182
Eisai Inc.10$181
Gilead(2 entities)9$164
Sobi, Inc5$162
GSK8$158
Pharmacyclics LLC, An Abbvie Company6$154
Stemline Therapeutics Inc.7$152
Daiichi Sankyo Inc.7$139
Beone Medicines USA, Inc.7$129
Regeneron Healthcare Solutions, Inc.7$128
Beigene USA, Inc.6$103
AbbVie5$100
Jazz Pharmaceuticals Inc.5$94
Rigel Pharmaceuticals, Inc.5$88
Pharmacosmos Therapeutics Inc.4$86
Ipsen Biopharmaceuticals, Inc3$82
Progenics Pharmaceuticals, Inc.4$80
EMD Serono, Inc.3$73
Sumitomo Pharma America, Inc.3$61
Boehringer Ingelheim2$57
Servier Pharmaceuticals LLC3$49
Blueprint Medicines Corporation2$48
Sanofi2$46
Mirati Therapeutics, Inc.2$44
Immunocore Limited1$44
Genentech USA, Inc.2$42
Recordati_rare_diseases_inc.2$37
Karyopharm Therapeutics Inc.2$35
Dendreon Pharmaceuticals LLC1$32
Puma Biotechnology, Inc.2$32
Exelixis Inc.1$29
GE HealthCare1$25
AMAG Pharmaceuticals, Inc.1$22
Deciphera Pharmaceuticals Inc.1$21
Agios Pharmaceuticals, Inc.1$21
Fennec Pharmaceuticals, Inc.1$21
Kyowa Kirin, Inc.1$20
Taiho Oncology, Inc.1$19
AVEO Pharmaceuticals, Inc.1$19
Global Blood Therapeutics, Inc.1$17
Myriad Genetic Laboratories, Inc.1$17
Coherus Oncology, Inc.1$14
Spectrum Pharmaceuticals Inc.1$14
Acceleron Pharma, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,696 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$231,953
Medicare patients
170
Services billed
29,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$27,749
Ondansetron Hcl13$1,734
Fentanyl16$1,082
Anastrozole31$883
Hydroxyurea40$826
Oxycodone Hcl22$521
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$459
Ondansetron OdtOndansetron11$238
Letrozole12$218
Gabapentin17$199
Testosterone Cypionate12$190
Prednisone13$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$591$27,74937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Gadsden

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →